Evaluation of the efficacy of 50% autologous serum eye drops in different ocular surface pathologies

Francesco Semeraro, Eliana Forbice, Osvaldo Braga, Alessandro Bova, Attilio Di Salvatore, Claudio Azzolini, Francesco Semeraro, Eliana Forbice, Osvaldo Braga, Alessandro Bova, Attilio Di Salvatore, Claudio Azzolini

Abstract

Purpose: This study evaluated the efficacy of 50% autologous serum eye drops in ocular surface diseases not improved by conventional therapy.

Methods: We analyzed two groups: (1) acute eye pathologies (e.g., chemical burns) and (2) chronic eye pathologies (e.g., recurrent corneal erosion, neurotropic keratitis, and keratoconjunctivitis sicca). The patients were treated for surface instability after conventional therapy. The patients received therapy 5 times a day until stabilization of the framework; they then reduced therapy to 3 times a day for at least 3 months. We analyzed the best corrected visual acuity, epithelial defects, inflammation, corneal opacity, and corneal neovascularization. We also analyzed symptoms such as tearing, burning, sense of foreign body or sand, photophobia, blurred vision, and difficulty opening the eyelids.

Results: We enrolled 15 eyes in group 1 and 11 eyes in group 2. The average therapy period was 16 ± 5.86 weeks in group 1 and 30.54 ± 20.33 weeks in group 2. The epithelial defects all resolved. Signs and symptoms improved in both groups. In group 2, the defect recurred after the suspension of therapy in 2 (18%) patients; in group 1, no defects recurred.

Conclusions: Autologous serum eye drops effectively stabilize and improve signs and symptoms in eyes previously treated with conventional therapy.

Figures

Figure 1
Figure 1
Clinical evolution of a patient with neurotrophic keratitis due to trigeminal nerve injury that occurred during acoustic neuroma excision.
Figure 2
Figure 2
Evolution of clinical signs in group 1 and group 2. All data significantly improved.
Figure 3
Figure 3
Evolution of visual acuity in the patients in the 2 groups. AS = autologous serum; p1–p15 = patient 1–patient 15.

References

    1. Noble BA, Loh RSK, MacLennan S, et al. Comparison of autologous serum eye drops with conventional therapy in a randomised controlled crossover trial for ocular surface disease. British Journal of Ophthalmology. 2004;88(5):647–652.
    1. Quinto GG, Campos M, Behrens A. Autologous serum for ocular surface diseases. Arquivos Brasileiros de Oftalmologia. 2009;71(6):47–54.
    1. Stern ME, Beuerman RW, Fox RI, Gao J, Mircheff AK, Pflugfelder SC. The pathology of dry eye: the interaction between the ocular surface and lacrimal glands. Cornea. 1998;17(6):584–589.
    1. Stern ME, Gao J, Siemasko KF, Beuerman RW, Pflugfelder SC. The role of the lacrimal functional unit in the pathophysiology of dry eye. Experimental Eye Research. 2004;78(3):409–416.
    1. Rolando M. Sjögren’s syndrome as seen by an ophthalmologist. Scandinavian Journal of Rheumatology, Supplement. 2001;30(115):27–33.
    1. Ralph RA, Doane MG, Dohlman CH. Clinical experience with a mobile ocular perfusion pump. Archives of Ophthalmology. 1975;93(10):1039–1043.
    1. Fox RI, Chan R, Michelson JB, Belmont JB, Michelson PE. Beneficial effect of artificial tears made with autologous serum in patients with keratoconjunctivitis sicca. Arthritis and Rheumatism. 1984;27(4):459–461.
    1. Tsubota K, Goto E, Fujita H, et al. Treatment of dry eye by autologous serum application in Sjogren’s syndrome. British Journal of Ophthalmology. 1999;83(4):390–395.
    1. Jeng BH. Use of autologous serum in the treatment of ocular surface disorders. Archives of Ophthalmology. 2011;129(12):1610–1612.
    1. Tsubota K, Goto E, Shimmura S, Shimazaki J. Treatment of persistent corneal epithelial defect by autologous serum application. Ophthalmology. 1999;106(10):1984–1989.
    1. Poon AC, Geerling G, Dart JKG, Fraenkel GE, Daniels JT. Autologous serum eyedrops for dry eyes and epithelial defects: clinical and in vitro toxicity studies. British Journal of Ophthalmology. 2001;85(10):1188–1197.
    1. Young AL, Cheng ACO, Ng HK, Cheng LL, Leung GYS, Lam DSC. The use of autologous serum tears in persistent corneal epithelial defects. Eye. 2004;18(6):609–614.
    1. Schrader S, Wedel T, Moll R, Geerling G. Combination of serum eye drops with hydrogel bandage contact lenses in the treatment of persistent epithelial defects. Graefe’s Archive for Clinical and Experimental Ophthalmology. 2006;244(10):1345–1349.
    1. Jeng BH, Dupps WJ., Jr. Autologous serum 50% eyedrops in the treatment of persistent corneal epithelial defects. Cornea. 2009;28(10):1104–1108.
    1. Choi JA, Chung S-H. Combined application of autologous serum eye drops and silicone hydrogel lenses for the treatment of persistent epithelial defects. Eye and Contact Lens. 2011;37(6):370–373.
    1. Rocha EM, Pelegrino F, De Paiva CS, Vigorito AC, De Souza ÇA. GVHD dry eyes treated with autologous serum tears. Bone Marrow Transplantation. 2000;25(10):1101–1103.
    1. Tananuvat N, Daniell M, Sullivan LJ, et al. Controlled study of the use of autologous serum in dry eye patients. Cornea. 2001;20(8):802–806.
    1. Takamura E, Shinozaki K, Hata H, Yukari J, Hori S. Efficacy of autologous serum treatment in patients with severe dry eye. Advances in Experimental Medicine and Biology. 2002;506:1247–1250.
    1. Ogawa Y, Okamoto S, Mori T, et al. Autologous serum eye drops for the treatment of severe dry eye in patients with chronic graft-versus-host disease. Bone Marrow Transplantation. 2003;31(7):579–583.
    1. Geerling G, MacLennan S, Hartwig D. Autologous serum eye drops for ocular surface disorders. British Journal of Ophthalmology. 2004;88(11):1467–1474.
    1. Kojima T, Ishida R, Dogru M, et al. The effect of autologous serum eyedrops in the treatment of severe dry eye disease: a prospective randomized case-control study. American Journal of Ophthalmology. 2005;139(2):242–246.
    1. Leite SC, de Castro RS, Alves M, et al. Risk factors and characteristics of ocular complications, and efficacy of autologous serum tears after haematopoietic progenitor cell transplantation. Bone Marrow Transplantation. 2006;38(3):223–227.
    1. Noda-Tsuruya T, Asano-Kato N, Toda I, Tsubota K. Autologous serum eye drops for dry eye after LASIK. Journal of Refractive Surgery. 2006;22(1):61–66.
    1. Yoon K-C, Heo H, Im S-K, You I-C, Kim Y-H, Park Y-G. Comparison of autologous serum and umbilical cord serum eye drops for dry eye syndrome. American Journal of Ophthalmology. 2007;144(1):e86–e92.
    1. Lee GA, Chen SX. Autologous serum in the management of recalcitrant dry eye syndrome. Clinical and Experimental Ophthalmology. 2008;36(2):119–122.
    1. Urzua CA, Vasquez DH, Huidobro A, Hernandez H, Alfaro J. Randomized double-blind clinical trial of autologous serum versus artificial tears in dry eye syndrome. Current Eye Research. 2012;37(8):684–688.
    1. Phasukkijwatana N, Lertrit P, Liammongkolkul S, Prabhasawat P. Stability of epitheliotrophic factors in autologous serum eye drops from chronic Stevens-Johnson syndrome dry eye compared to non-autoimmune dry eye. Current Eye Research. 2011;36(9):775–781.
    1. Matsumoto Y, Dogru M, Goto E, et al. Autologous serum application in the treatment of neurotrophic keratopathy. Ophthalmology. 2004;111(6):1115–1120.
    1. del Castillo JM, de la Casa JM, Sardiña RC, et al. Treatment of recurrent corneal erosions using autologous serum. Cornea. 2002;21(8):781–783.
    1. Ziakas NG, Boboridis KG, Terzidou C, et al. Long-term follow up of autologous serum treatment for recurrent corneal erosions. Clinical and Experimental Ophthalmology. 2010;38(7):683–687.
    1. Goto E, Shimmura S, Shimazaki J, Tsubota K. Treatment of superior limbic keratoconjunctivitis by application of autologous serum. Cornea. 2001;20(8):807–810.
    1. Panda A, Jain M, Vanathi M, Velpandian T, Khokhar S, Dada T. Topical autologous platelet-rich plasma eyedrops for acute corneal chemical injury. Cornea. 2012;31(9):989–993.
    1. Sharma N, Goel M, Velpandian T, Titiyal JS, Tandon R, Vajpayee RB. Evaluation of umbilical cord serum therapy in acute ocular chemical burns. Investigative Ophthalmology and Visual Science. 2011;52(2):1087–1092.
    1. Wilson SE, Chen L, Mohan RR, Liang Q, Janice L. Expression of HGF, KGF, EGF and receptor messenger RNAs following corneal epithelial wounding. Experimental Eye Research. 1999;68(4):377–397.
    1. Kokawa N, Sotozono C, Nishida K, Kinoshita S. High total TGF-β2 levels in normal human tears. Current Eye Research. 1996;15(3):341–343.
    1. Tseng SCG, Farazdaghi M, Rider AA. Conjunctival transdifferentiation induced by systemic vitamin A deficiency in vascularized rabbit corneas. Investigative Ophthalmology and Visual Science. 1987;28(9):1497–1504.
    1. Uno K, Kuroki M, Hayashi H, Uchida H, Kuroki M, Oshima K. Impairment of thrombospondin-1 expression during epithelial wound healing in corneas of vitamin A-deficient mice. Histology and Histopathology. 2005;20(2):493–499.
    1. Kim EC, Kim TK, Park SH, Kim MS. The wound healing effects of vitamin A eye drops after a corneal alkali burn in rats. Acta Ophthalmologica. 2012;90(7):e540–e546.
    1. Kojima T, Higuchi A, Goto E, Matsumoto Y, Dogru M, Tsubota K. Autologous serum eye drops for the treatment of dry eye diseases. Cornea. 2008;27(1):S25–S30.
    1. Costagliola C, Romano V, Forbice E, et al. Corneal oedema and its medical treatment. Clinical and Experimental Optometry. 2013;96(6):529–535.
    1. Nishida T, Nakamura M, Ofuji K, Reid T, Mannis M, Murphy C. Synergistic effects of substance P with insulin-like growth factor-1 on epithelial migration of the cornea. Journal of Cellular Physiology. 1996;169(1):159–166.
    1. Liu L, Hartwig D, Harloff S, et al. Corneal epitheliotrophic capacity of three different blood-derived preparations. Investigative Ophthalmology and Visual Science. 2006;47(6):2438–2444.
    1. Geerling G, Daniels JT, Dart JKG, Cree IA, Khaw PT. Toxicity of natural tear substitutes in a fully defined culture model of human corneal epithelial cells. Investigative Ophthalmology and Visual Science. 2001;42(5):948–956.
    1. Noecker R. Effects of common ophthalmic preservatives on ocular health. Advances in Therapy. 2001;18(5):205–215.
    1. Dua HS, King AJ, Joseph A. A new classification of ocular surface burns. British Journal of Ophthalmology. 2001;85(11):1379–1383.
    1. Liu L, Hartwig D, Harloff S, Herminghaus P, Wedel T, Geerling G. An optimised protocol for the production of autologous serum eyedrops. Graefe’s Archive for Clinical and Experimental Ophthalmology. 2005;243(7):706–714.
    1. López-García JS, García-Lozano I. Use of containers with sterilizing filter in autologous serum eyedrops. Ophthalmology. 2012;119(11):2225–2230.
    1. Cho YK, Huang W, Kim GY, Lim BS. Comparison of autologous serum eye drops with different diluents. Current Eye Research. 2013;38(1):9–17.
    1. Marquez De Aracena Del Cid R, Montero De Espinosa Escoriaza I. Subconjunctival application of regenerative factor-rich plasma for the treatment of ocular alkali burns. European Journal of Ophthalmology. 2009;19(6):909–915.
    1. Fischer KR, Opitz A, Böeck M, Geerling G. Stability of serum eye drops after storage of 6 months. Cornea. 2012;31(11):1313–1318.
    1. Gupta A, Monroy D, Ji Z, Yoshino K, Huang A, Pflugfelder SC. Transforming growth factor beta-1 and beta-2 in human tear fluid. Current Eye Research. 1996;15(6):605–614.
    1. Terai K, Call MK, Liu H, et al. Crosstalk between TGF-β and MAPK signaling during corneal wound healing. Investigative Ophthalmology and Visual Science. 2011;52(11):8208–8215.
    1. Aragona P, Papa V, Micali A, Santocono M, Milazzo G. Long term treatment with sodium hyaluronate-containing artificial tears reduces ocular surface damage in patients with dry eye. British Journal of Ophthalmology. 2002;86(2):181–184.
    1. Jirsova K, Brejchova K, Krabcova I, et al. The application of autologous serum eye drops in severe dry eye patients; subjective and objective parameters before and after treatment. Current Eye Research. 2014;39(1):21–30.
    1. Mantelli F, Tranchina L, Lambiase A, Bonini S. Ocular surface damage by ophthalmic compounds. Current Opinion in Allergy and Clinical Immunology. 2011;11(5):464–470.
    1. Tincani A, Andreoli L, Cavazzana I, et al. Novel aspects of Sjögren’s syndrome in 2012. BMC Medicine. 2013;11(1, article 93)
    1. Semeraro F, Angi M, Romano M, Filippelli M, Di Iorio R, Costagliola C. Neurotrophic keratitis. Ophthalmologica. 2014;231(4):191–197.
    1. López-García JS, Rivas L, García-Lozano I, Murube J. Autologous serum eyedrops in the treatment of aniridic keratopathy. Ophthalmology. 2008;115(2):262–267.
    1. Clare G, Suleman H, Bunce C, Dua H. Amniotic membrane transplantation for acute ocular burns. Cochrane Database of Systematic Reviews. 2012;9CD009379
    1. Wagoner MD, Kenyon KR, Gipson IK. Polymorphonuclear neutrophils delay corneal epithelial wound healing in vitro. Investigative Ophthalmology and Visual Science. 1984;25(10):1217–1220.
    1. Pfister RR, Burstein N. The effects of ophthalmic drugs, vehicles, and preservatives on corneal epithelium: a scanning electron microscope study. Investigative Ophthalmology. 1976;15(4):246–259.
    1. Berman M, Manseau E, Law M, Aiken D. Ulceration is correlated with degradation of fibrin and fibronectin at the corneal surface. Investigative Ophthalmology and Visual Science. 1983;24(10):1358–1366.
    1. Hayashi K, Berman M, Smith D, El-Ghatit A, Pease S, Kenyon KR. Pathogenesis of corneal epithelial defects: role of plasminogen activator. Current Eye Research. 1991;10(5):381–398.
    1. Berman M, Leary R, Gage J. Evidence for a role of the plasminogen activator-plasmin system in corneal ulceration. Investigative Ophthalmology and Visual Science. 1980;19(10):1204–1221.
    1. Márquez-de-Aracena R, Montero-de-Espinosa I, Muñoz M, Pereira G. Subconjunctival application of plasma platelet concentrate in the treatment of ocular burns. Preliminary results. Archivos de la Sociedad Espanola de Oftalmologia. 2007;82(8):475–481.
    1. Granelli-Piperno A, Vassalli JD, Reich E. Secretion of plasminogen activator by human polymorphonuclear leukocytes. Modulation by glucocorticoids and other effectors. Journal of Experimental Medicine. 1977;146(6):1693–1706.
    1. Imanishi J, Kamiyama K, Iguchi I, Kita M, Sotozono C, Kinoshita S. Growth factors: importance in wound healing and maintenance of transparency of the cornea. Progress in Retinal and Eye Research. 2000;19(1):113–129.
    1. Kobayashi TK, Tsubota K, Takamura E, Sawa M, Ohashi Y, Usui M. Effect of retinol palmitate as a treatment for dry eye: a cytological evaluation. Ophthalmologica. 1997;211(6):358–361.

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться